Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 RSVPreF3 OA single-dose and revaccination schedules in adults ≥60 years
jRCT2071200089Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Primary endpoint: RSV-A neutralizing antibody GMT (ED60). Started Feb 2021; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2071200089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200089.